TSH Receptor Antibody Measurement in Methimazole-Treated Graves' Disease
Measure TRAb at the end of methimazole treatment (typically 12-18 months) and use levels ≥3.85 IU/L as a threshold to guide against drug discontinuation, as this predicts >96% risk of relapse. 1
When to Measure TRAb
- At diagnosis: Confirm Graves' disease etiology, as TRAb has >95% sensitivity and specificity for diagnosis 2
- At 12 months of treatment: TRAb >7.5 IU/L at this timepoint predicts >90% risk of relapse 2
- At cessation of antithyroid drug therapy (typically 18 months): This is the most critical measurement for discontinuation decisions 1, 3
How TRAb Results Guide Discontinuation
High-Risk Patients (Favor Definitive Treatment Over Discontinuation)
- TRAb >12 IU/L at diagnosis: Associated with 60% relapse risk at 2 years and 84% at 4 years 2
- TRAb >7.5 IU/L at 12 months: Predicts >90% relapse risk 2
- TRAb ≥3.85 IU/L at cessation: 96.7% positive predictive value for relapse; all but one patient with levels above this threshold relapsed after methimazole withdrawal 1
For these patients, consider definitive treatment with radioactive iodine or thyroidectomy rather than discontinuing methimazole. 2 RAI is preferred unless moderate-to-severe Graves' ophthalmopathy is present, in which case thyroidectomy is favored. 2
Low-Risk Patients (Safe to Discontinue)
- TRAb <0.9 IU/L at end of treatment: All patients with levels this low remained euthyroid throughout follow-up 1
- Negative TRAb by third-generation assay: Significantly lower relapse rates (35.42% vs 54.84% in TRAb-positive patients) 4
Discontinuation of methimazole is reasonable when both TSI and TRAb are negative. 4
Intermediate-Risk Patients (0.9-3.85 IU/L)
This range does not reliably discriminate between patients who will relapse versus remain euthyroid. 1 However, patients in this range who do relapse typically do so later (median 56 weeks) compared to high TRAb patients (median 8 weeks), and relapse is accompanied by rising TRAb levels. 1
For intermediate-risk patients, consider extending minimum maintenance dose therapy beyond 18 months, as longer treatment duration (≥19 months) significantly improves remission rates. 5
Additional Monitoring Considerations
- During treatment: TRAb levels decline with antithyroid drug therapy but remain significantly elevated compared to healthy controls even after 18 months 1
- Minimum maintenance dose duration: Remission rates increase with longer minimum maintenance dose therapy (one tablet every other day); patients with ≥19 months of minimum maintenance dose have significantly higher remission rates than those with ≤6 months 5
- TRAb-positive patients with short minimum maintenance dose: Do not discontinue methimazole in TRAb-positive patients who have received ≤6 months of minimum maintenance dose therapy, as they have significantly lower remission rates 5
Special Populations
- Women of childbearing age: Early ablative treatment (RAI or surgery) should be considered in those at higher risk of relapse, as methimazole use in early pregnancy is associated with congenital anomalies 6, 2
- Pregnant women: TRAb ≥5 IU/L indicates increased risk of fetal and neonatal thyrotoxicosis requiring close monitoring 2
- Patients with Graves' ophthalmopathy: Elevated TRAb is an indication for steroid prophylaxis to prevent progression with RAI therapy 2
Common Pitfalls
- Relying solely on clinical euthyroidism: 75.9% of patients remain TRAb-positive at the end of 18-month treatment despite being clinically euthyroid 1
- Premature discontinuation: The cumulative methimazole dose requirement is significantly higher in TRAb-positive patients, and time to remission is longer 7
- Ignoring TRAb trends: Rising TRAb levels after initial decline predict relapse even in patients with initially low levels 1